{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2"}]}],"title":"ADA positive at Baseline"},{"categories":[{"measurements":[{"groupId":"OG000","value":"5"}]}],"title":"ADA positive at post-baseline"}],"denoms":[{"counts":[{"groupId":"OG000","value":"93"}],"units":"Participants"}],"description":"Number of participants with positive ADA titer to tisotumab vedotin at baseline and post-baseline are reported. Baseline is defined as the latest available measurement made before the first dose of tisotumab vedotin. For post-baseline results, a participant was considered ADA positive if either ADA is negative at baseline and at least one post-baseline result is positive or positive at baseline and at least one positive post-baseline result with a titer higher than baseline.","groups":[{"description":"Participants received IV tisotumab vedotin 2.0 mg/kg Q3W until radiographic disease progression verified by the IRC, unacceptable AEs requiring drug discontinuation, withdrawal of consent, lost to follow up or death, whichever occurred first.","id":"OG000","title":"Tisotumab Vedotin"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Participants in FAS (received at least 1 dose of tisotumab vedotin) and who had ADA results at baseline and post-baseline are analyzed for this outcome measure.","reportingStatus":"POSTED","timeFrame":"Predose of each treatment cycle (Cycle 1 to 21) and end of treatment visit (approximately 49 months)","title":"Number of Participants With Positive Anti-drug Antibodies (ADA) to Tisotumab Vedotin","type":"SECONDARY","unitOfMeasure":"Participants"}